Nira R. Pollock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nira R. Pollock has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Alex Sloutsky
2 shared publicationsAntonio Campos-Neto
2 shared publicationsEdward Nardell
2 shared publicationsJasmine Guillet
2 shared publicationsMichael Wong
2 shared publicationsSwati Joshi
2 shared publications
Latest Publications
- 19 September 2012
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 4 (152) , 152ra129
A Paper-Based Multiplexed Transaminase Test for Low-Cost, Point-of-Care Liver Function Testing
A paper-based, multiplexed microfluidic assay allows rapid, semiquantitative, visual measurement of transaminases in clinical specimens.
- 19 September 2012
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 4 (152) , 152ra129
A Paper-Based Multiplexed Transaminase Test for Low-Cost, Point-of-Care Liver Function Testing
A paper-based, multiplexed microfluidic assay allows rapid, semiquantitative, visual measurement of transaminases in clinical specimens.
- Open Access
- 15 September 2009
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 49 (6) , e66-e68
Ruling Out Novel H1N1 Influenza Virus Infection with Direct Fluorescent Antigen Testing
We evaluated the ability of direct fluorescent antigen (DFA) influenza tests to identify novel H1N1 influenza virus. DFA results were compared with p
- 15 September 2009
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 49 (6) , e66-e68
Open AccessRuling Out Novel H1N1 Influenza Virus Infection with Direct Fluorescent Antigen Testing
We evaluated the ability of direct fluorescent antigen (DFA) influenza tests to identify novel H1N1 influenza virus. DFA results were compared with p
- 1 April 2009
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 30 (4) , 392-395
Evaluation of the Effect of Treatment of Latent Tuberculosis Infection on QuantiFERON-TB Gold Assay Results
To evaluate the utility of the QuantiFERON-TB Gold assay for monitoring latent tuberculosis treatment efficacy, the assay was performed serially for healthcare workers receiving isoniazid therapy. After 9 months of isoniazid therapy, all of these healthcare workers remained QuantiFERON-TB Gold positive, and cellular proliferation assays revealed persistently strong purified protein derivative responses. These results do not support the use of the QuantiFERON-TB Gold assay to monitor therapy.
- 1 April 2009
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 30 (4) , 392-395
Evaluation of the Effect of Treatment of Latent Tuberculosis Infection on QuantiFERON-TB Gold Assay Results
To evaluate the utility of the QuantiFERON-TB Gold assay for monitoring latent tuberculosis treatment efficacy, the assay was performed serially for healthcare workers receiving isoniazid therapy. After 9 months of isoniazid therapy, all of these healthcare workers remained QuantiFERON-TB Gold positive, and cellular proliferation assays revealed persistently strong purified protein derivative responses. These results do not support the use of the QuantiFERON-TB Gold assay to monitor therapy.
- 1 September 2008
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 29 (9) , 878-886
Discordant QuantiFERON-TB Gold Test Results Among US Healthcare Workers With Increased Risk of Latent Tuberculosis Infection: A Problem or Solution?
Objective.: In late 2006, our hospital implemented use of the QuantiFERON-TB Gold (QFT-G) assay, a whole-blood interferon-γ release assay, for detection of tuberculosis infection. All newly hired healthcare workers (HCWs) with positive Mantoux tuberculin skin test (TST) results were routinely tested with the QFT-G assay, to take advantage of its higher specificity. We then undertook a quality assurance review to evaluate the QFT-G test results in HCWs with multiple risk factors for latent tuberculosis infection (LTBI).Methods.: The clinical records for TST-positive HCWs tested with the QFT-G assay were reviewed. HCWs with 2 or more risk factors commonly associated with LTBI were classified as “increased risk” (IR). IR HCWs who had negative QFT-G test results underwent repeat QFT-G testing and were offered testing with a different interferon-γ release assay (T-SPOT.TB) and with extended T cell stimulation assays.Results.: Ofl43 TST-positive HCWs tested with the QFT-G assay, 26 (18%) had positive results, 115 (81%) had negative results, and 2 (1 %) had indeterminate results. Of 82 IR HCWs, 23 (28%) had positive QFT-G test results, and 57 (70%) had negative results. Of the 57 IR HCWs with negative results, 43 underwent repeat QFT-G testing: 41 had negative results again, and 2 had positive results. These 43 HCWs were also offered additional testing with the T-SPOT.TB diagnostic, and 36 consented: 31/36 tested negative, and 5/36 tested positive. Extended assays using the antigens ESAT-6 and CFP-10 confirmed the positive results detected by the overnight assays and yielded positive results for an additional 7/36 (19%) of individuals; strikingly, all 36 HCWs had strongly positive test results with assays using purified protein derivative.Conclusions.: The extreme discordance between the results of our clinical diagnostic algorithm and the results of QFT-G testing raises concern about the sensitivity of the QFT-G assay for detection of LTBI in our HCWs. Results of extended stimulation assays suggest that many of our IR HCWs have indeed been sensitized to Mycobacterium tuberculosis. It is possible that the QFT-G assay identifies those at higher reactivation risk rather than all previously infected, but, in the absence of long-term follow-up data, we should interpret negative QFT-G results with some caution.
- 1 September 2008
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 29 (9) , 878-886
Discordant QuantiFERON-TB Gold Test Results Among US Healthcare Workers With Increased Risk of Latent Tuberculosis Infection: A Problem or Solution?
Objective.: In late 2006, our hospital implemented use of the QuantiFERON-TB Gold (QFT-G) assay, a whole-blood interferon-γ release assay, for detection of tuberculosis infection. All newly hired healthcare workers (HCWs) with positive Mantoux tuberculin skin test (TST) results were routinely tested with the QFT-G assay, to take advantage of its higher specificity. We then undertook a quality assurance review to evaluate the QFT-G test results in HCWs with multiple risk factors for latent tuberculosis infection (LTBI).Methods.: The clinical records for TST-positive HCWs tested with the QFT-G assay were reviewed. HCWs with 2 or more risk factors commonly associated with LTBI were classified as “increased risk” (IR). IR HCWs who had negative QFT-G test results underwent repeat QFT-G testing and were offered testing with a different interferon-γ release assay (T-SPOT.TB) and with extended T cell stimulation assays.Results.: Ofl43 TST-positive HCWs tested with the QFT-G assay, 26 (18%) had positive results, 115 (81%) had negative results, and 2 (1 %) had indeterminate results. Of 82 IR HCWs, 23 (28%) had positive QFT-G test results, and 57 (70%) had negative results. Of the 57 IR HCWs with negative results, 43 underwent repeat QFT-G testing: 41 had negative results again, and 2 had positive results. These 43 HCWs were also offered additional testing with the T-SPOT.TB diagnostic, and 36 consented: 31/36 tested negative, and 5/36 tested positive. Extended assays using the antigens ESAT-6 and CFP-10 confirmed the positive results detected by the overnight assays and yielded positive results for an additional 7/36 (19%) of individuals; strikingly, all 36 HCWs had strongly positive test results with assays using purified protein derivative.Conclusions.: The extreme discordance between the results of our clinical diagnostic algorithm and the results of QFT-G testing raises concern about the sensitivity of the QFT-G assay for detection of LTBI in our HCWs. Results of extended stimulation assays suggest that many of our IR HCWs have indeed been sensitized to Mycobacterium tuberculosis. It is possible that the QFT-G assay identifies those at higher reactivation risk rather than all previously infected, but, in the absence of long-term follow-up data, we should interpret negative QFT-G results with some caution.